Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Aligos Therapeutics's ALG-009?
ALG-009 is a small molecule commercialized by Aligos Therapeutics, with a leading Phase II program in Metabolic Dysfunction-Associated Steatohepatitis (MASH);Liver...
ALG-009 by Aligos Therapeutics for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
ALG-009 is under clinical development by Aligos Therapeutics and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to...
ALG-009 by Aligos Therapeutics for Liver Fibrosis: Likelihood of Approval
ALG-009 is under clinical development by Aligos Therapeutics and currently in Phase II for Liver Fibrosis. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Aligos Therapeutics's ALG-009?
ALG-009 is a small molecule commercialized by Aligos Therapeutics, with a leading Phase II program in Metabolic Dysfunction-Associated Steatohepatitis (MASH)....